Life Science Compliance Update



Through the Worm Hole (Part 3) – Setting a Standard for GP Compliance

Written by , Posted in Pricing

Chris Cobourn, Managing Director, Huron Life Sciences

This is Part 3 of a series of articles designed to help life sciences compliance professionals understand the complex, and sometimes contradictory, universes of publicly funded health programs, such as Medicaid and Medicare, and the impact on participating drug manufacturers. This article focuses on the how to evaluate GP Compliance, what manufacturers should do to ensure that they are in full compliance with the programs, and the role of the Compliance Office.


Topic tags:

Menu Title